Beam Therapeutics Inc. logo

Beam Therapeutics Inc.

NASDAQ:BEAM

Overview | Financials
Company Name Beam Therapeutics Inc.
Symbol BEAM
Currency USD
Price 16.8
Market Cap 1,689,357,600
Dividend Yield 0%
52-week-range 13.525 - 35.25
Industry Biotechnology
Sector Healthcare
CEO Mr. John M. Evans M.B.A.
Website https://www.beamtx.com

An error occurred while fetching data.

About Beam Therapeutics Inc.

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor

Related Stocks

PTC Therapeutics, Inc. logo

PTC Therapeutics, Inc.

PTCT

49.84 USD

Tilray Brands, Inc. logo

Tilray Brands, Inc.

TLRY

0.401 USD

Arvinas, Inc. logo

Arvinas, Inc.

ARVN

7.54 USD

EQRx, Inc. logo

EQRx, Inc.

EQRX

2.34 USD

Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc.

IOVA

1.69 USD

Corcept Therapeutics Incorporated logo

Corcept Therapeutics Incorporated

CORT

73.22 USD

Insmed Incorporated logo

Insmed Incorporated

INSM

99.49 USD

AbCellera Biologics Inc. logo

AbCellera Biologics Inc.

ABCL

3.61 USD

Fate Therapeutics, Inc. logo

Fate Therapeutics, Inc.

FATE

1.04 USD

Canopy Growth Corporation logo

Canopy Growth Corporation

CGC

1.22 USD

Financials

Numbers are in millions USD

Numbers are in millions USD